Litcius/Paper detail

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes

Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, Alberto Álvarez‐Larrán, Arianna Ghirardi, Greta Carioli, Francesca Fenili, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Laura Calabresi, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesco Ramundo, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Daniele Cattaneo, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi, Alessandro M. Vannucchi

2023Annals of Hematology19 citationsDOIOpen Access PDF

Topics & Concepts

PhlebotomyMedicineTolerabilityClinical endpointPolycythemia veraInternal medicineAdverse effectHematologyBloodlettingSurrogate endpointHematocritDrugRandomized controlled trialSurgeryPharmacologyPathologyAlternative medicineMyeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and SyndromesHemoglobinopathies and Related Disorders
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes | Litcius